For and Against Routine Removal of Peripheral Intravenous Catheters

Tomer Meirson; Adam Goldman; David Bomze

doi:10.1001/jamainternmed.2021.8301

For and Against Routine Removal of Peripheral Intravenous Catheters

Tomer Meirson
, Adam Goldman
, David Bomze

Rabin Medical Center–Beilinson Hospital
Tel Aviv University

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	455-456
Number of pages	2
Journal	JAMA Internal Medicine
Volume	182
Issue number	4
DOIs	https://doi.org/10.1001/jamainternmed.2021.8301
State	Published - 1 Apr 2022
Externally published	Yes

Bibliographical note

Funding Information:
payments to her institution for speaking engagements from 3M, Becton Dickinson, Cardinal Health, and Eloquest, outside the submitted work. Dr Paterson reported funding from AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; board membership for Janssen, Entasis, Qpex, Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; grants from Pfizer, Shionogi, and Merck; speaking fees from Pfizer, all outside the submitted work. No other disclosures were reported.

Funding

payments to her institution for speaking engagements from 3M, Becton Dickinson, Cardinal Health, and Eloquest, outside the submitted work. Dr Paterson reported funding from AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; board membership for Janssen, Entasis, Qpex, Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; grants from Pfizer, Shionogi, and Merck; speaking fees from Pfizer, all outside the submitted work. No other disclosures were reported.

Funders
Cubist
Leo Pharmaceuticals
Pfizer
AstraZeneca
Bayer
GlaxoSmithKline
Merck
Shionogi

Access to Document

10.1001/jamainternmed.2021.8301

Cite this

@article{8bb1128440c04037928a114dc3c37bba,

title = "For and Against Routine Removal of Peripheral Intravenous Catheters",

author = "Tomer Meirson and Adam Goldman and David Bomze",

note = "Funding Information: payments to her institution for speaking engagements from 3M, Becton Dickinson, Cardinal Health, and Eloquest, outside the submitted work. Dr Paterson reported funding from AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; board membership for Janssen, Entasis, Qpex, Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; grants from Pfizer, Shionogi, and Merck; speaking fees from Pfizer, all outside the submitted work. No other disclosures were reported.",

year = "2022",

month = apr,

day = "1",

doi = "10.1001/jamainternmed.2021.8301",

language = "אנגלית",

volume = "182",

pages = "455--456",

journal = "JAMA Internal Medicine",

issn = "2168-6106",

publisher = "American Medical Association",

number = "4",

}

TY - JOUR

T1 - For and Against Routine Removal of Peripheral Intravenous Catheters

AU - Meirson, Tomer

AU - Goldman, Adam

AU - Bomze, David

N1 - Funding Information: payments to her institution for speaking engagements from 3M, Becton Dickinson, Cardinal Health, and Eloquest, outside the submitted work. Dr Paterson reported funding from AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; board membership for Janssen, Entasis, Qpex, Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; grants from Pfizer, Shionogi, and Merck; speaking fees from Pfizer, all outside the submitted work. No other disclosures were reported.

PY - 2022/4/1

Y1 - 2022/4/1

UR - https://www.scopus.com/pages/publications/85124995502

U2 - 10.1001/jamainternmed.2021.8301

DO - 10.1001/jamainternmed.2021.8301

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 35156993

AN - SCOPUS:85124995502

SN - 2168-6106

VL - 182

SP - 455

EP - 456

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

IS - 4

ER -

For and Against Routine Removal of Peripheral Intravenous Catheters

Bibliographical note

Funding

Access to Document

Other files and links

Cite this